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Diversity in a simple co-crystal: racemic and
kryptoracemic behaviour†
U. B. Rao Khandavilli,a Matteo Lusi,b Balakrishna R. Bhogala,a Anita R. Maguire,c
Matthias Steind and Simon E. Lawrence*a
The crystal structure containing ()-3-methyl-2-phenylbutyramide
with salicylic acid is the first example of a kryptoracemate co-crystal.
It exhibits the first temperature mediated reversible single-crystal to
single-crystal transition between two kryptoracemate forms, in addition
to crystallising in another, racemic, form. Theoretical calculations and
structural analysis reveal that there are only small diﬀerences in both
energy and packing arrangements between the three forms. These
results suggest that co-crystals can be an opportunity to investigate
kryptoracemate behaviour.
Understanding the solid state behaviour of organic compounds
has become increasingly important in a variety of fields over the
past three decades.1–4 Co-crystallization is one approach that
has garnered interest since the generation of families of related
materials provides an opportunity to modulate targeted physico-
chemical properties over a broad range. For this reason it has
been explored in a variety of fields including pharmaceuticals,5–9
nutraceuticals,10–12 agrochemicals,13,14 explosives,15–18 solid-state
photochemistry,19,20 chiral resolution,21–23 etc. Recently, the US
Food and Drug Administration recognised the importance of
co-crystals and issued guidelines for their use in the pharmaceutical
sector.24 Separation of enantiomers has developed in recent years,
particularly with the advent of Viedma ripening.25–27 Enantiomer
separation using co-crystallization is less well investigated in
comparison to salt formation,28,29 even though it is, in theory,
more applicable since it does not require the presence of an
ionisable functional group in the molecule of interest.2 With this
background, we have chosen to investigate the co-crystallisation
behaviour of ()-3-methyl-2-phenylbutyramide, 1, an anti-mitotic
compound.30
In our co-crystallisation screening of 1 we obtained co-crystals
with salicylic acid, 1SA. Structural analysis revealed the co-crystal
crystallised in a Sohncke (chiral) space group with both enan-
tiomers present in the asymmetric unit. Racemic compounds
which crystallise in chiral space groups yet remain racemic (i.e.
maintain a 1 : 1 ratio of enantiomers) are rare, with limited
discussion found in the literature.31–37 Morales & Fronczek
coined the term ‘‘kryptoracemate’’ for these systems in
1996.31 Fa´bia´n and Brock examined their occurrence amongst
organic molecules by analysing the Cambridge Structural Database
(CSD) in 2010; finding only 151 organic kryptoracemate structures
at that time.34 Very recently, Laubenstein et al. examined the
first example of a molecule crystallising in both racemic and
kryptoracemic structures,36 and a second example has just been
published.37 To the best of our knowledge the co-crystal of 1
with salicylic acid is the first co-crystal kryptoracemate. Further
work uncovered a racemic form, plus the first example of a
single-crystal to single-crystal transformation between two
kryptoracemic forms.
Initially, 1SA was isolated from dichloromethane at room
temperature. Single crystal X-ray diﬀraction reveals that at room
temperature the crystals are in the orthorhombic space group
P212121; Form I. Upon cooling to 100 K on the diﬀractometer,
Form I transformed to the lower symmetry monoclinic Sohncke
space group P21 (Form II). Variable temperature single crystal
X-ray diﬀraction confirmed that the transformation between the
two forms is reversible, occurring between 150 K and 250 K (ESI†).
Crystallisation screening using various solvents and solvent
mixtures by crystallization from a solution at room temperature
failed to produce Form II, although in some cases a novel
racemic polymorph of 1SA (Form III) was observed concomitantly
with Form I (ESI†). This new form crystallises in the centro-
symmetric space group P21/c. Pure Form III was obtained from
dichloromethane at 0 1C. Thus, it was possible to obtain pure
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samples of Forms I and III for further analysis, whereas Form II
could only be obtained upon cooling of Form I, as summarised
in Scheme 1.
The three polymorphs were further investigated by spectro-
scopic techniques. The IR and Raman spectra of Forms I and III
are almost identical, with only very slight variations observed in
the lattice vibrational region (ESI†). Powder X-ray diﬀraction,
PXRD, data for the bulk material is consistent with the single
crystal data for both Form I and III (ESI†), highlighting that the
structural analyses obtained from the single crystal experiments
are representative of the bulk material. DSC thermograms
between RT and 150 1C indicate no interconversion between
these two forms and show that Form I is the lower melting
polymorph (85–88 1C for Form I vs. 86–89 1C for Form III).
Melting of Form III requires higher energy (3.4 vs. 4.7 W g1)
suggesting that it is the most stable polymorph (ESI†).
All three forms have similar unit cell axes and volumes,
diﬀering only in one unit cell angle (ESI†). In Form I there are
two symmetry independent salicylic acid molecules along with
two molecules of 1 (designated R1 & S2) and since it is a non-
centrosymmetric structure there are no corresponding S1 and
R2 molecules present. In Form II, four symmetry independent
salicylic acid molecules and corresponding amide molecules
(R1, S2, R3 and S4) are present. Form III has two symmetry
independent salicylic acidmolecules and two amidemolecules (R1
and S2) and, being centrosymmetric, S1 and R2 are also present.
The molecular conformations in the three forms are very
similar, the main diﬀerences being slight variations in the
torsion angles between the phenyl group and the chiral centre
of 1 (Fig. 1 and ESI†). In each case, the hydroxyl group of the
salicylic acid is involved in intramolecular O–H  O hydrogen
bonding [S(6) using Etter’s notation38,39] and is not involved in
the formation of the supramolecular architecture. This beha-
viour is common for salicylic acid and other ortho-substituted
hydroxyl carboxylic acids.40–42 The three forms all exhibit
hydrogen bonding from a salicylic acid molecule to one molecule
of 1 (either R or S) via the well-known 8-membered acid-amide
R22(8) heterosython and one-dimensional tapes via C(4)
N–H  OQC hydrogen bonding catamers, using the anti N–H
hydrogen atom (Fig. 1). The tapes alternate between R and S
enantiomers of 1, Fig. 2. Differences between the three forms
are due to the spatial arrangement of these tapes. In Form I,
tape A is related to tapes B, C and D by a 21 screw axis along the
x, z and y axes, respectively. The tapes A0 and B0 are in the
adjacent unit cell to A and B. Form II has a very similar spatial
arrangement to Form I. The tapes are slipped relative to one
another along the monoclinic direction causing the loss of
symmetry and the shortening of the p–p interactions between
the salicylic acid from about 3.9 Å (Form I) to 3.6 Å (Form II),
Fig. 3. Loss of the two 21 screw symmetries along the a and c
axes means there is an increase in the number of symmetry
independent molecules present in the lattice (from Z0 = 2 to 4).
In Form III the tapes are arranged in anti-parallel fashion along
both the b and c axes over crystallographic inversion centres.
In general, solid state transitions between polymorphs occur
through reconstructive, topotactic or epitactic mechanisms and
are usually activated by heat, light or mechanical stress.43–47
Often this results in significant loss of crystallinity due to the
restricted molecular mobility in crystals and, hence, single-
crystal to single-crystal transitions are relatively rare in organic
compounds. The similar crystal packing in Forms I and II
enables the rationalisation of the single-crystal to single-crystal
reversible transformation. Solid-state transformation between
Forms I and III was not observed; most likely because the
inversion centre in Form III requires a reconstructive pathway
for interconversion between the parallel (Form I) and anti-
parallel (Form III) packing arrangements.
High Z0 values have been discussed in an extensive review by
Steed and Steed.4 In this context 1SA oﬀers an opportunity
to determine the energy relationship between structures with
diﬀerent Z0 values (Form I vs. Form II) and whether the
kryptoracemates are metastable with respect to the centro-
symmetric racemate (Form II vs. Form III). According to Oswald’s
rule of stages, metastable forms crystallize first and the thermo-
dynamically stable forms crystallize later.48–50 In the recent study
by Laubenstein et al., the kryptoracemate was initially identified
and three centrosymmetric polymorphs subsequently found in
a polymorphic screen.36 Therefore, we have investigated the
energies of the three forms of 1SA with periodic DFT calculations
Scheme 1 Schematic representation of the co-crystallization outcomes.
Fig. 1 The hydrogen bonding in Form 1 showing the 1-D chain and acid-
amide dimers, left, and overlay of all three forms (red = Form I, violet = Form II
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using the revPBE functional with dispersion correction. These
confirm the monoracemate Form III to be the minimum
structure. Forms I and II are very close in energy and inter-
conversion between them seems to be possible without large
distortions. It must be noted that the large unit cells with
hundreds of atoms, hydrogen bonding interactions in planes
and subtle p-interactions between them pose a challenge to
current theoretical approaches.
The relative stability of Forms I and III was investigated by
slurrying in HPLC-grade water for 48 hours (ESI†). There was no
change observed for the experiments involving the pure forms.
Form III was the only product observed for the experiments
beginning with mixtures of the two forms, highlighting that
Form III is the more stable form, in agreement with the
computational and DSC data.
Price et al. noted the large number of known and predicted
structures for organic compounds and suggested that it is
unlikely that crystallization will result in the formation of only
one racemic or two separate enantiopure crystal forms.51 Their
work on mandelic acids showed a range of thermodynamically
feasible structures of enantiopure and racemic forms with
similar energies. In our work, even though these kryptoracemate
co-crystals have only one chiral component, their similar lattice
energies suggest that kryptoracemates may need to be considered
when designing processes for chiral separation, especially as
their presence is an obstacle to this overall goal.
In summary, we have reported two kryptoracemates and one
racemate of a co-crystal containing ()-3-methyl-2-phenylbutyramide
with salicylic acid. The two kryptoracemates are enantiotropically
related by a reversible phase transition that can be observed in
single crystals. The relationship between the kryptoracemates
and the racemate is diﬃcult to determine with high accuracy
both experimentally and computationally. It will be interesting
to see whether kryptoracemates remain metastable forms with
respect to their racemic counterparts for other systems, or are
genuinely the most thermodynamically stable form.
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Crystallize.
Fig. 2 Packing diagrams of Form I–III highlighting the parallel (Forms I
and II) and anti-parallel (Form III) arrangement of the N–H  OQC C(4)
hydrogen bonded catamers (blue arrows indicate H  O direction, blue
box for clarity of catamers). Symmetry related molecules have the same
colour for the C and H atoms and the molecules are labelled with their
chirality. Only the amide functional group of 1 and H-bond connectivity are
shown for clarity. Magenta dots indicate the inversion centre in Form III.
Fig. 3 p–p interactions in Form I (left) and Form II (right) viewed
perpendicular to the ab and bc plane respectively. The red arrow shows
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